Physician profile
Robert N Todd
NPI 1770104507
$683.40
in general payments reported to CMS, 2019-2025
15 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $50.15 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101.76 | 2025 | |
| Pfizer INC. | $94.40 | 2024-2025 | |
| Novo Nordisk INC | $82.13 | 2025 | Wegovy |
| Lilly USA, LLC | $70.74 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $58.34 | 2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $52.98 | 2024-2025 | |
| Glaxosmithkline, LLC. | $44.68 | 2025 | Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $38.86 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $31.93 | 2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.28 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $19.11 | 2025 | Heplisav-B |
| Paratek Pharmaceuticals, INC. | $15.05 | 2025 | Nuzyra, Xhance |
| Esperion Therapeutics, INC. | $14.69 | 2025 | Nexletol |
| Exact Sciences Corporation | $14.34 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $14.11 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.